source
- Cue Biopharma's CUE-221 meets primary endpoint in phase 2 CSU trial, eyes phase 2b/3Cue Biopharma reported that its chronic spontaneous urticaria (CSU) candidate CUE-221 achieved the primary endpoint in a midstage study conducted in China. The trial enrolled 145 patients who rece…
- Addiction clinics see rising cases of kratom and 7-OH withdrawalAddiction clinics are seeing a surge in patients dependent on potent kratom and 7-OH products.